On September 30, 2025, uniQure N.V. announced the closing of an upsized underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, including 947,368 shares issued upon full exercise of the underwriters’ option to purchase additional shares. The aggregate gross proceeds from the offering were approximately $345 million before underwriting discounts and commissions.
The company stated that the net proceeds will be used to fund commercialization readiness activities for AMT‑130, support the potential commercial launch of the Huntington’s disease therapy, advance other clinical product candidates, pursue business development initiatives, and cover general corporate purposes.
Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen acted as bookrunning managers for the offering, with H.C. Wainwright & Co. serving as lead manager. The offering was conducted under uniQure’s automatically effective shelf registration statement on Form S‑3 filed with the SEC on January 7, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.